Several studies performed over the last 6 years provide direct evidence that hypoxia in experimental rodent tumours and human tumour xenografts can result from intermittent non-perfusion of tumour blood vessels (Chaplin et al., 1986a (Chaplin et al., , 1987 Jirtle, 1988; Minchinon et al., 1990; Trotter et al., 1989; Chaplin & Trotter, 1991) . If hypoxia in human tumours results at least in part from such temporal changes in microregional perfusion many of the approaches for improving tumour oxygenation; e.g. breathing high-oxygen content gases with and without perfluorochemical emulsions would prove ineffective at reoxygenating all of the radiobiologically-resistant hypoxic cells. Indeed although there is evidence that such approaches can produce improvements in the radiation response of tumours, overall, the results in both experimental rodent tumours and in clinical trials have been disappointing. (Teicher & Rose, 1984; Rockwell, 1985 Rockwell, , 1987 Song et al., 1985; Rockwell et al., 1986; Rubin et al., 1979; Sasai et al., 1989) .
One strategy to improve the effectiveness of such therapy would be to combine it with a treatment which can prevent the temporal microregional fluctuations in blood flow within the tumour. Recent studies by us have identified nicotinamide and pyrazinamide as agents which can reduce and/or eliminate such intermittent changes in tumour blood flow (Horsman et al., 1990; Chaplin et al., 1990a,b; Horsman, 1992) .
Based on these findings we proposed (Chaplin et al., 1990a; Horsman et al., 1990) and demonstrated that combining nicotinamide with carbogen and perfluorochemical emulsions could provide large enhancements of the response of the SCCVII tumour to single doses of radiation. Subsequently in a series of elegant experiments Kjellen et al. (1991) and Rojas (1991) have shown large enhancements of tumour radiation response when nicotinamide and carbogen are used in clinically relevant multifraction treatments. All of these studies have utilised nicotinamide at doses between 500-1,000 mg kg-I which may not be achievable in a clinical setting. Recent, preliminary reports have indicated that significant enhancement of tumour radiation response can be achieved when carbogen breathing is combined with nicotinamide doses as low as 100 mg kg- . Another factor which can influence the efficacy of any therapeutic strategy which utilises carbogen breathing is the effect of preirradiation breathing time (PIBT) (Siemann et al., 1977) . In the present study we have continued our investigation of nicotinamide and carbogen by evaluating the importance of both nicotinamide dose and carbogen PIBT on the radiation response of the murine SCCVII tumour.
Materials and methods
Mice and tumour SCCVII tumours were obtained by injecting 106 tumour cells subcutaneously over the sacral region of the back in 6-9 week old female C3H/He mice (Charles River Inc., Quebec, Canada). Tumours were used in the size range 500-850 mg for in vivo/in vitro assays, this size was attained 10-15 days following implantation. placing the mice in individual perspex boxes which were lead shielded. A portion of lead was cut out to expose the posterior dorsum bearing the tumour to a horizontal i.e. laterally directed X-ray beam (270 kv dose rate 2.9 Gy min-1). To ensure that the tumour was fully exposed to the X-ray beam, a cardboard wedge was placed when necessary under the hind feet. Four mice were mounted as two pairs in front of two collimated appertures on a plate which fitted on the head of the X-ray set. To ensure uniform doses throughout the tumour volume, the mice were turned through 1800 halfway through each irradiation.
Carbogen breathing
Animals were placed in their individual plexiglass/lead boxes in the irradiation set-up. A plexiglass cover was then placed over the set-up and clipped into place. The system was then gassed with Carbogen (95% 02, 5% C02) for various times prior to and during irradiation.
Preparation of tumour cell suspensions The animals were sacrificed and tumours excised 18-20 h after irradiation. Following excision, the tumours were washed with PBS, chopped using crossed scalpels, and weighed. The resulting fragments, after being washed with PBS, were disaggregated by gentle agitation for 30 min with an enzyme cocktail of trypsin (0.2%), DNase (0.05%) and collagnease (0.05%) at 37°C. The resulting cell suspension was filtered through polyester mesh (50 ytm pore size), centrifuged, and the cell pellet resuspended in medium. Cell suspensions were routinely counted with the aid of a haemocytometer enabling tumour cell yield to be ascertained. The mean cell yields for tumours in this series of experiments was 5.6 x 107 g ' of tissue.
Measurement of cell survival Tumour cell viability was assessed using the soft agar clonogenic assay described previously (Courtenay, 1976) . Known numbers of tumour cells were pated into soft agar and cultured in a water saturated atmosphere of 5% 02, 5% CO2 and 90% N2 for 14 days. Tumour colonies of more than 50 cells were counted with the aid of a microscope. For the present series of experiments, the plating efficiency for untreated tumours ranged between 0.35 and 0.62. The effect of treatment on cell survival was expressed as the fraction of surviving cells per tumour, that is: = S.F x cell yield/g treated cell yield/g untreated Results Figure 1 shows the response of 500-850 mg tumours to increasing X-ray doses. Also shown is the response of SCCVII cells in vitro under aerobic conditions. It can be observed that tumour cells irradiated in vivo are more resistant to radiation doses > 10 Gy than those irradiated in vitro. The resistance is due in large part to hypoxic cells as it can be reduced or eliminated using hypoxic cell radiosensitisers (Chaplin et al., 1986b) . In order to study the effect of a strategy which reduces tumour hypoxia we chose a radiation dose of 14 Gy. Treating tumours with such a radiation dose results in a large differential between the survival response of fully aerobic cells and the radiobiologically hypoxic tumour cells in the tumour but remains within the survival range of our assay procedures. Figure 2 shows the effect of pre-irradiation breathing time (PIBT) with carbogen on the radiation response of SCCVII tumours. It can be seen that in this tumour the optimum PIBT is between 5 and 30 min. The sensitising effect decreases with increasing time after 30 min with little or no radiosensitisation being observed after Radiation dose (Gray) Figure 1 The effect of X-ray dose on the survival of SCCVII tumour cells (@) when irradiated as 500-850 mg tumours in vivo, Nicotinamide dose (mg kg-) Figure 3 The effect of nicotinamide dose on the radiation response of 500-850 mg kg-' SCCVII tumours, mice were given nicotinamide alone 60 min prior to irradiation (0), nicotinamide plus carbogen breathing PIBT -60 min (0) Figure 3 that significant sensitisation is observed with nicotinamide at doses as low as 100 mg kg-' in combination with carbogen. Figure 4 shows the radiation dose response of the SCCVII tumour following treatments in which nicotinamide at doses of 1,000, 250 and 100 mg kg-' IP was combined with carbogen breathing (PIBT 60 min). It can be seen that over the radiation dose range examined the response for the combinations in which 1,000 and 250 mg kg-' nicotinamide are used are indistinguishable from that expected for an aerobic response. Significant enhancement of radiation response is also observed in treatment combinations in which 100 mg kg-' of nicotinamide is used.
Discussion
There is growing interest in the possible use of nicotinamide and carbogen in clinical radiotherapy trials (Horsman, 1992; Rojas et al., 1992 250-500 mg) (Chaplin et al. unpublished studies) . Our studies demonstrate that variations in radiation response of the SCCVII are seen with carbogen PIBT, which is consistent with previous reports in other tumours (Siemann et al., 1977) . However, no variation in such response for PIBT between 5 and 60 min is observed if nicotinamide (1,000 mg kg-1) is combined with carbogen. Indeed the response observed in Figure 2 for this combination is consistent with that for a fully aerobic response. If these studies are applicable to human studies it would suggest that strict control of PIBT may not be necessary to achieve the therapeutic benefit when nicotinamide is combined with carbogen.
The question as to what dose of nicotinamide will be achievable in the clinic has not been answered as yet, although doses of up to 6 g are clinically acceptable (Zackheim et al., 1981) . Recent pharmacokinetic studies in humans have now utilised nicotinamide doses of up to 6 g (Horsman, 1992; Stratford et al., 1992) . The study by Horsman has suggested that in the mouse, sensitisation is linked to peak plasma levels. The human pharmacokinetic studies indicate that 6 g of nicotinamide will produce a peak plasma level of between 120-190 fg ml-' and that the same plasma level is achieved in mice with a dose of 100-200 mg kg-' (Horsman, 1992) . In our present study using the SCCVII tumour, a fully aerobic radiation survival response is achieved using a nicotinamide dose of 250 mg kg-' when combined with carbogen breathing. If nicotinamide operates by similar mechanism in fractionated radiotherapy in human tumours as it does in single radiation doses in mouse tumours and the effect depends on peak plasma levels, then a dose of 8-9 g given to humans in combination with carbogen could produce similar effects to those seen with 250 mg kg-' nicotinamide plus carbogen in our murine system. It can be seen from Figure 4 that a dose of nicotinamide as low as 100mgkg-' when combined with carbogen breathing produces a level of sensitisation equivalent to reoxygenating i .A p --80% of the hypoxic cells in this tumour and an equivalent dose in humans can be achieved. Significant enhancements of radiation/carbogen combinations by nicotinamide at doses as low as 100 mg kg-' have also been indicated in a preliminary report by Rojas et al. (1992) in the Carcinoma NT. One other implication from the present study, when compared to our previous report , is that little or no benefit is achieved in the SCCVII tumour by the adjuvant use of the perfluorochemical emulsion Fluosol DA with the nicotinamide and carbogen combination i.e. similar enhancements in tumour cell kill can be achieved in the nicotinamide carbogen breathing combination in the presence or absence of perfluorochemical emulsions. However it is possible that such adjuvant treatment may prove beneficial in other tumour types particularly if nicotinamide does not facilitate the resumption of erythrocyte flow in some vessels.
Several reservations have been raised regarding the use of nicotinamide and carbogen in clinical radiotherapy (Brown, 1992) . These were: (1) Could levels of nicotinamide required to achieve radiosensitisation in mice be achieved in man? (2) Could radiosensisation be achieved at radiation doses used in clinical radiotherapy? (3) Could carbogen breathing improve the oxygen tension within human tumours to the same degree as it does in mouse tumours? (4) Is the occurrence of perfusion limited hypoxia and/or the ability of nicotinamide to reduce it, a phenomenon only found in transplantable murine tumours? The first three of these points have been addressed to some extent in recent publications (Falk et al., 1992; Horsman, 1992; Rojas et al., 1992) . The last point cannot as yet be definitively addressed since the techniques currently available for quantitating perfusion limited hypoxia can not be used in the clinic. However, there is no reason to believe that non-perfusion of vessels does not contribute to the level of radiobiological hypoxia in human tumours. A positive outcome of clinical trials with nicotinamide and carbogen is currently the only way of providing, albeit indirectly, evidence for this.
In summary, the present studies have continued our investigation into the use of nicotinamide to improve radiation response of tumours via a reduction in tumour hypoxia. The results support our previous data and confirm that nicotinamide when combined with breathing of high oxygen content gasses can dramatically improve the tumours' radiation response. Moreover this effect is seen at nicotinamide doses which appear to be achievable in the clinic. Although more work with such treatment strategies is warranted including studies with spontaneous tumours, these results together with other available data strongly suggest that nicotinamide and carbogen should be evaluated as a treatment to improve the response to radiotherapy in the clinic, particularly in tumour sites where hypoxia is considered one of the limiting factors.
